



ASX ANNOUNCEMENT

4 April, 2023

SUCCESSFUL PLACEMENT OF SHORTFALL SHARES FROM RIGHTS ISSUE

Melbourne, Australia – Opyl Limited (ASX:OPL) is pleased to announce that it has successfully raised a further \$124,622 (before costs) via the issue of all 4,154,059 shortfall shares at an issue price of \$0.03 per share under the shortfall facility of the rights issue, which closed on 13 February 2023.

The shares under the shortfall have been taken up by new and existing sophisticated and professional investors with an interest or background in healthtech and efficiency technologies. New investors have acknowledged the growth potential of the company's clinical trial recruitment solution Opin.ai, and expressed particular interest in expanding development of TrialKey, the company's emerging clinical trial design and prediction technology that harnesses artificial intelligence and big data to improve the probability of delivering a successful clinical trial result.

The additional funding from the shortfall allows the company, at minimal cost, to advance development of TrialKey, to a minimum viable product (MVP stage) and into a pilot with existing global pharma customers. Advancing development to this point is a necessary pre-condition to viably be able to demonstrate the platform's capabilities and attract partners interested and capable of accelerating the development and commercialisation of the platform. Further, these development cost are likely to be eligible for R&D tax incentives.

This shortfall placement together with the support for the rights issue has raised approximately \$480,390 (before costs) through the issue of 16,013,013 new fully paid ordinary shares. The shares on issue at the completion is as follows:

Description	Number of shares
Existing shares on issues at time of offer	64,052,052
Rights issue shares	11,858,954
Shortfall shares	4,154,059
Total shares issued	16,013,013
Total shares on issue	80,065,065

The Board and management team is very appreciative of the support shown by both existing and new shareholders through the capital raisings, that has provided vital funding to support the company's growth and development.

The Board has authorised this announcement for release to the ASX.

-ENDS-



For media and investor enquiries:

E: info@opyl.a

www.opyl.ai

For clinical trial recruitment enquiries:

E: info@opyl.a

www.opin.ai

About Opyl Limited

Opyl is a new generation Australian digital health company that applies artificial intelligence to improving clinical trials. Our platforms make clinical trials more efficient and easier to access, giving patients more options and saving medical researchers time and money.

Our key offering for biopharma, medtech, government and healthcare organisations:

- clinical trial recruitment solutions – Opin.ai
- clinical trial predictive analytics and protocol design – TrialKey
- deep social media insights and analysis – Social Insights

Follow Opyl on Twitter (@Opylai), LinkedIn and Facebook

For personal use only